Dynavax Technologies logo

Dynavax TechnologiesNASDAQ: DVAX

Profile

Sector:

Healthcare

Country:

United States

IPO:

19 February 2004

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.61 B
-27%vs. 3y high
79%vs. sector
-55%vs. 3y high
91%vs. sector
-92%vs. 3y high
64%vs. sector
-26%vs. 3y high
67%vs. sector

Price

after hours | Sat, 16 Nov 2024 00:16:57 GMT
$12.21-$0.90(-6.86%)

Dividend

No data over the past 3 years
$80.63 M$71.71 M
$80.63 M$17.59 M

Analysts recommendations

Institutional Ownership

DVAX Latest News

Dynavax Technologies: What The Stock Buyback Means.  What It Doesn't
seekingalpha.com13 November 2024 Sentiment: POSITIVE

Today, we revisit Dynavax Technologies Corporation, whose shares have moved up nicely after the company announced a significant buyback authorization. In addition, DVAX's flagship product Heplisav-B continues to increase market share consistently in a growing market. The company has also moved towards profitability and analyst firms have price targets significantly above the current trading level of the stock, even after its recent rally.

Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
zacks.com11 November 2024 Sentiment: POSITIVE

Dynavax Technologies (DVAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts Predict an 88.32% Upside in Dynavax Technologies (DVAX): Here's What You Should Know
zacks.com11 November 2024 Sentiment: POSITIVE

The consensus price target hints at an 88.3% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Dynavax Announces $100 Million Accelerated Share Repurchase Program
prnewswire.com11 November 2024 Sentiment: POSITIVE

EMERYVILLE, Calif. , Nov. 11, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has entered into an Accelerated Share Repurchase transaction ("ASR") under an agreement with Goldman Sachs & Co. LLC to repurchase $100 million of the Company's common stock.

Glancy Prongay & Murray LLP Announces Investigation of Dynavax Technologies Corporation (DVAX)
businesswire.com06 November 2024 Sentiment: NEGATIVE

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Dynavax Technologies Corporation (Nasdaq: DVAX) concerning the Company and its directors' and officers' possible violations of state laws. If you own Dynavax stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York, NY 1016.

Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024
prnewswire.com24 October 2024 Sentiment: POSITIVE

EMERYVILLE, Calif. , Oct. 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2024 financial results on Thursday, November 7, 2024, after the U.S. financial markets close.

3 'Repeatable' Biotech Trades
seekingalpha.com25 September 2024 Sentiment: POSITIVE

Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churning out profits is by embracing using covered call orders to establish positions in small-cap biotech names. Many of these have become consistent profitable “rinse, wash and repeat” trades over the years.

Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
seekingalpha.com23 August 2024 Sentiment: NEUTRAL

Dynavax has experienced fluctuations in stock performance since the author's initial coverage. HEPLISAV-B is Dynavax's primary revenue source for the foreseeable future, with CpG-1018 currently sidelined. Supported by ample liquidity, Dynavax is evaluating business development on a disciplined basis.

How Much Upside is Left in Dynavax Technologies (DVAX)? Wall Street Analysts Think 135.98%
zacks.com09 August 2024 Sentiment: POSITIVE

The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 136% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Dynavax Technologies (DVAX) Tops Q2 Earnings Estimates
zacks.com06 August 2024 Sentiment: POSITIVE

Dynavax Technologies (DVAX) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago.

  • 1(current)
  • 2

What type of business is Dynavax Technologies?

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

What sector is Dynavax Technologies in?

Dynavax Technologies is in the Healthcare sector

What industry is Dynavax Technologies in?

Dynavax Technologies is in the Drug Manufacturers - Specialty & Generic industry

What country is Dynavax Technologies from?

Dynavax Technologies is headquartered in United States

When did Dynavax Technologies go public?

Dynavax Technologies initial public offering (IPO) was on 19 February 2004

What is Dynavax Technologies website?

https://www.dynavax.com

Is Dynavax Technologies in the S&P 500?

No, Dynavax Technologies is not included in the S&P 500 index

Is Dynavax Technologies in the NASDAQ 100?

No, Dynavax Technologies is not included in the NASDAQ 100 index

Is Dynavax Technologies in the Dow Jones?

No, Dynavax Technologies is not included in the Dow Jones index

When was Dynavax Technologies the previous earnings report?

No data

When does Dynavax Technologies earnings report?

The next expected earnings date for Dynavax Technologies is 21 February 2025